

Mark C. Holscher (SBN 139582)  
KIRKLAND & ELLIS LLP  
555 South Flower Street, Suite 3700  
Los Angeles, CA 90071  
Telephone (213) 680-8400  
Facsimile: (213) 680-8500  
Email: mark.holscher@kirkland.com

Christopher W. Keegan (SBN 232045)  
Anna Terteryan (SBN 300368)  
KIRKLAND & ELLIS LLP  
555 California Street, Suite 2700  
San Francisco, CA 94104  
Telephone: (415) 439-1400  
Facsimile: (415) 439-1500  
Email: chris.keegan@kirkland.com  
Email: anna.terteryan@kirkland.com

Gabor Balassa (admitted *pro hac vice*)  
Ryan Moorman (admitted *pro hac vice*)  
KIRKLAND & ELLIS LLP  
333 West Wolf Point Plaza  
Chicago, IL 60654  
Telephone: (312) 862-2000  
Facsimile: (312) 862-2200  
Email: gbalassa@kirkland.com  
Email: ryan.moorman@kirkland.com

*Counsel for Defendant and Counter-Claimant  
Eli Lilly and Company*

QUINN EMANUEL URQUHART &  
SULLIVAN, LLP  
Diane M. Doolittle (Bar No. 142046)  
dianedoolittle@quinnemanuel.com  
Yury Kapgan (Bar No. 218366)  
yurykapgan@quinnemanuel.com  
Kyle Batter (Bar No. 301803)  
kylebatter@quinnemanuel.com  
555 Twin Dolphin Drive, 5th Floor  
Redwood Shores, California 94065  
Telephone: (650) 801-5000  
Facsimile: (650) 801-5100

David M. Elihu (Bar No. 303043)  
davideliu@quinnemanuel.com  
Sarah Cork (Bar No. 330569)  
sarahcork@quinnemanuel.com  
865 South Figueroa Street, 10th Floor  
Los Angeles, California 90017  
Telephone: (213) 443-3000  
Facsimile: (213) 443-3100

Brendan Carroll (admitted *pro hac vice*)  
brendancarroll@quinnemanuel.com  
51 Madison Avenue, 22nd Floor  
New York, NY 10010  
Telephone: (212) 849-7000  
Facsimile: (212) 849-7000

*Counsel for Plaintiff and Counter-Defendant  
Nektar Therapeutics*

**UNITED STATES DISTRICT COURT  
NORTHERN DISTRICT OF CALIFORNIA  
SAN FRANCISCO DIVISION**

NEKTAR THERAPEUTICS,  
  
Plaintiff/Counter-Defendant,  
  
v.  
  
ELI LILLY & CO.,  
  
Defendant/Counter-Claimant.

CASE NO. 3:23-CV-03943-JD

**STIPULATION AND ~~PROPOSED~~ ORDER  
RE AMENDED PLEADINGS, ENLARGING  
MOTION TO DISMISS BRIEFING  
SCHEDULE**

Judge: Hon. James Donato  
Hearing Date: June 20, 2024  
Time: 10:00 a.m.  
Courtroom: 11

1 Pursuant to Civil Local Rules 6-1 and 6-2, Plaintiff Nektar Therapeutics (“Plaintiff”) and  
2 Defendant Eli Lilly and Company (“Defendant”), by and through their undersigned counsel, hereby  
3 stipulate and agree as follows:

4 WHEREAS, on March 29, 2024, Defendant filed and served its Counterclaims, Answer, and  
5 Affirmative Defenses (ECF No. 54) (“Counterclaims & Answer”) to Plaintiff’s original complaint in this  
6 matter (ECF No. 1) (“Original Complaint”);

7 WHEREAS, on April 26, 2024, Plaintiff filed and served its Motion to Dismiss Defendant’s  
8 Counterclaims (“Motion”) (ECF No. 58), and noticed it for a hearing on June 20, 2024 at 10:00 am P.T.;

9 WHEREAS, on May 3, 2024, Plaintiff filed and served its First Amended Complaint (ECF No.  
10 61) (“Amended Complaint”);

11 WHEREAS Plaintiff’s Amended Complaint added allegations regarding Lilly’s alleged failure to  
12 return materials under the License Agreement, but is otherwise substantially similar to Plaintiff’s Original  
13 Complaint;

14 WHEREAS, the parties wish to avoid submitting duplicative or unnecessary pleadings and filings,  
15 in the interest of judicial efficiency;

16 WHEREAS the parties have previously stipulated and/or sought leave to modify case deadlines  
17 four times in this case, *see* (ECF Nos. 19, 42, 51, 56);

18 WHEREAS the parties now agree to extend Defendant’s time to respond to Plaintiff’s Motion and  
19 Plaintiff’s time to reply, which extensions will not impact any other deadline related to the Motion or this  
20 case;

21 NOW THEREFORE, the parties hereby stipulate and agree, subject to the Court’s approval, as  
22 follows:

- 23 1. Defendant’s previous Counterclaims & Answer shall remain the operative pleading in response  
24 to Plaintiff’s claims in this case and applies to the Amended Complaint, and Defendant denies  
25 all new allegations in the Amended Complaint, except to the extent they purport to characterize  
26 the July 2017 co-development and license agreement between Plaintiff and Defendant (the  
27 “Agreement”), which speaks for itself, in which case Defendant denies any allegations  
28 inconsistent with the Agreement;

2. The time for Defendant to file and serve its opposition to Plaintiff's Motion is hereby extended from May 10, 2024 to May 24, 2024.
3. Plaintiff shall file and serve its reply to Defendant's opposition by June 7, 2024.

DATED: May 10, 2024

Respectfully submitted,

KIRKLAND & ELLIS LLP

s/ Ryan Moorman

Ryan Moorman

*Counsel for Defendant and Counter-Claimant  
Eli Lilly and Company*

DATED: May 10, 2024

Respectfully submitted,

QUINN EMANUEL URQUHART & SULLIVAN, LLP

s/ Yury Kapgan

Yury Kapgan

*Counsel for Plaintiff and Counter-Defendant  
Nektar Therapeutics*

**ATTESTATION PURSUANT TO CIVIL L.R. 5-1(I)(3)**

I, Ryan Moorman, am the ECF user whose user ID and password are being used to file this document. I hereby attest that concurrence in the filing of this document has been obtained from each of the other signatories.

Ryan Moorman

Ryan Moorman

**PURSUANT TO STIPULATION, IT IS SO ORDERED:**

Dated May 14, 2024

  
\_\_\_\_\_  
HONORABLE JAMES DONATO  
UNITED STATES DISTRICT COURT JUDGE